Recombinant Human LILRA3 protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human LILRA3 protein (rFc Tag) (Eg2670)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg2670

---

Validation Data Gallery

• 

  Purity of Recombinant Human LILRA3 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human LILRA3 protein Gly24-Glu439 (Accession# Q8N6C8-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 11026
• Accession: Q8N6C8-1
• PredictedSize: 71.0 kDa
• SDS-PAGE: 70-90 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

LILRA3 (Leukocyte Immunoglobulin Like Receptor A3) is a member of the human leukocyte immunoglobulin-like receptor family and is the only soluble receptor in this group, also known as CD85e, ILT6, or LIR-4. LILRA3 is produced as a soluble molecule by monocytes and macrophages and exhibits the presence or absence of a 6.7 kb variant between individuals. LILRA3 is produced by monocytes and macrophages as a soluble molecule, and exhibits the presence or absence of a 6.7 kb variant between individuals. the 6.7 kb deletion consists of the first six of a total of seven exons and removes all four Ig-like structural domains, resulting in a truncated protein. lILRA3 has been implicated as a novel susceptibility factor for systemic lupus erythematosus (SLE) and primary desiccation syndrome (pSS). variants of the lILRA3 gene have been associated with increased susceptibility to autoimmune diseases, including prophylactic lupus. increased susceptibility, including primary Sjogren's syndrome (SS) and non-Hodgkin's B-cell lymphoma (B-NHL).

References:

1. Wu X, et al. (2021). Iran J Basic Med Sci. 24(2):196-202.                                               
2. Liu H, et al. (2022). Rheumatology (Oxford). 8;61(12):4962-4974.                              
3. Ryu M, et al. (2011). PLoS One. 6(4):e19245.                                                             
4. Wang H, et al. (2019). Front Genet. 10:869.